Pepgen inc.PEPG.US Overview

US StockHealthcare

(No presentation for PEPG)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

PEPG Overall Performance

PEPG AI Analysis & Strategy

PEPG Recent Performance

0.82%

Pepgen inc.

0.81%

Avg of Sector

-1.14%

S&P500

PEPG PowerScanner

PEPG Key Information

PEPG Valuation Metrics

PEPG Earnings Table

PEPG Profile

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.